CSBR

$6.20

Post-MarketAs of Mar 17, 8:00 PM UTC

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$6.20
Potential Upside
5%
Whystock Fair Value$6.51
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based u...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$86.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-47.59%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.93

Recent News

Motley Fool
Mar 13, 2026

Champions Oncology (CSBR) Earnings Transcript

Robert Brainin: Good afternoon, and thank you for joining us for our third quarter fiscal 2026 earnings call. First, we delivered another quarter of strong operational performance, including record services revenue and our third consecutive quarter of positive adjusted EBITDA. Second, while quarterly revenue can fluctuate in our business, we remain on track for full year revenue growth and full year positive adjusted EBITDA while continuing to invest in both our data platform and our discovery therapeutics subsidiary.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 13, 2026

Champions Oncology, Inc. Q3 2026 Earnings Call Summary

Moby summary of Champions Oncology, Inc.'s Q3 2026 earnings call

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 20, 2026

Fund Discloses $25 Million Braze Stock Investment Amid 60% Share Plunge

This SaaS provider enables brands to personalize customer engagement across digital channels using data-driven orchestration tools.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 20, 2026

Battery Management Dumps $9 Million Zeta Stake as Shares Slide 38% Year Over Year

This marketing technology provider delivers data-driven automation and consumer insights to enterprise clients across multiple channels.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Feb 20, 2026

Battery Takes $124 Million Bet on Kodiak AI. Here's What Investors Should Know

Kodiak AI, Inc. delivers AI-powered navigation software for trucking, defense, and industrial fleets using proprietary sensor technology.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.